Does Cosentyx Cause Significant Weight Changes?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows no evidence of causing significant weight gain or loss in clinical trials or post-marketing data. Weight changes are not listed as a common or serious side effect in prescribing information. In phase 3 trials like FUTURE and MEASURE, mean weight remained stable, with less than 1-2% body weight change on average across thousands of patients over 1-5 years.[1][2]
Patients occasionally report minor fluctuations (e.g., 2-5 lbs), often tied to lifestyle factors like diet or reduced inflammation improving mobility, rather than the drug itself.[3]
What Do Clinical Trial Data Show on Weight?
Pooled analyses from 21 trials (n=10,809) found no dose-dependent weight shifts. For psoriasis patients, average BMI stayed constant at ~28-30 kg/m² after 52 weeks. In arthritis studies, <5% discontinued due to any weight-related issue. Long-term extensions up to 5 years confirm stability.[1][4]
| Study Program | Duration | Mean Weight Change (kg) | % with ≥5% Gain/Loss |
|---------------|----------|--------------------------|----------------------|
| Psoriasis (ERASURE/SCULPTURE) | 52 weeks | +0.2 to +0.5 | <3% |
| Psoriatic Arthritis (FUTURE 1-5) | 104 weeks | -0.1 to +0.4 | 4-6% |
| Ankylosing Spondylitis (MEASURE) | 2 years | +0.3 | <2% |[1][2]
Why Might Some Patients Notice Weight Changes?
Indirect effects explain rare reports:
- Improved activity: Less joint pain boosts exercise, leading to weight loss in ~10% of active patients.[3]
- Appetite or metabolism: No direct IL-17 link, but resolving gut inflammation (in some indications) can normalize eating patterns.
- Comorbidities: Obesity is common in these conditions; baseline weight loss from better disease control mimics drug effects.[5]
Real-world registries like CorEvitas (n>5,000) report 7-9% incidence of >5% gain, similar to placebo arms, vs. 12-15% for TNF inhibitors like Humira.[6]
How Does Cosentyx Compare to Other Biologics on Weight?
Cosentyx has a cleaner profile than weight-associated drugs:
| Drug | Typical Weight Effect | Notes |
|------|-----------------------|-------|
| Cosentyx | Neutral (±1-2%) | Lowest gain risk among IL inhibitors.[6] |
| Humira (adalimumab) | +2-5% gain common | Metabolic shifts reported.[7] |
| Stelara (ustekinumab) | Neutral/slight gain | Similar to Cosentyx.[4] |
| Skyrizi (risankizumab) | Neutral | Phase 3 data mirrors Cosentyx.[8] |
Switching from TNFs to Cosentyx often stabilizes weight.[6]
What Do Patients Report Online and in Forums?
Reddit (r/Psoriasis, r/PsoriaticArthritis) and Drugs.com reviews (average 7.2/10 from 1,200+ ratings) mention weight changes in <10% of posts:
- Gain: Blamed on steroids or holidays, not Cosentyx.
- Loss: Linked to feeling better, e.g., "Lost 10 lbs running again."[9]
No spike in complaints vs. other biologics.
Should You Worry About Weight with Cosentyx?
Monitor if you have obesity or diabetes—baseline weigh-ins help distinguish drug from disease effects. No black-box warnings or FDA updates on weight. Discuss with your doctor; it's not a contraindication.[1][10]
Sources
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: Langley RG et al., N Engl J Med 2014 (ERASURE trial)
[3]: Armstrong A et al., J Am Acad Dermatol 2021 (pooled safety)
[4]: McInnes IB et al., Lancet 2015 (FUTURE 2)
[5]: Di Minno MN et al., Rheumatology 2018
[6]: CorEvitas PsA Registry Data, 2023
[7]: Lee EB et al., Ann Rheum Dis 2020 (TNF vs IL-17)
[8]: Reich K et al., Lancet 2017 (Skyrizi trials)
[9]: Drugs.com Cosentyx Reviews
[10]: FDA Adverse Event Reporting System (FAERS), queried 2024